Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Cogstate Ltd (CGS AU)
Watchlist
12
Analysis
Health Care
•
Australia
CogState Limited manufactures and distributes diagnostic and therapeutic products associated with neurological disorders and the measurement of cognitive functions.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Cogstate Ltd
•
22 Oct 2022 01:57
•
Broker
Cogstate - Backlog Builds for Alzheimer's Trials, but Revenue Delayed
The clinical trials backlog is now $110.5m (+26% pcp), driven by another strong quarter of clinical trial sales of $17.9m (-56% pcp).
CCZ Statton Equities
Follow
143 Views
Share
bullish
•
Cogstate Ltd
•
01 Oct 2022 04:26
•
Broker
Cogstate - Lecanemab Strikes 'home Run' for Alzheimer's Drug Development
The drug reduced clinical cognitive decline by 27% compared to a placebo in a study involving 1,795 participants with early Alzheimer's disease.
CCZ Statton Equities
Follow
310 Views
Share
bullish
•
Cogstate Ltd
•
09 Sep 2022 08:00
•
Issuer-paid
Cogstate Ltd - Brain Health Is Driving the World and Revenues
Cogstate Ltd Brain health is driving the world and revenues Cogstate (ASX:CGS) works to optimise brain health assessments in clinical...
Research as a Service (RaaS)
Follow
522 Views
Share
bullish
•
Cogstate Ltd
•
03 Sep 2022 09:34
•
Broker
Cogstate - Phase 3 Readouts Underpin the Next Phase of Accelerated Growth
Largely pre-announced, CGS recorded a FY22 group revenue of $45.0m, up +38% pcp, with the clinical trial segment attributing $40.3m, up +41% pcp.
CCZ Statton Equities
Follow
209 Views
Share
Previous
1
2
3
Next
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.37.2
x